Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yasmin Shakur

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Handbook of Experimental Pharmacology|June 23, 2011
Phosphodiesterases as targets for intermittent claudicationYongge Liu, Yasmin Shakur, Junichi Kambayashi
BMC Microbiology|March 9, 2006
Cyclic nucleotide specific phosphodiesterases of Leishmania majorAndrea Johner, Stefan Kunz, Markus Linder, et al.
Current Pharmaceutical Design|October 8, 2003
Cilostazol as a unique antithrombotic agentJunichi Kambayashi, Yongge Liu, Bing Sun, et al.
Handbook of Experimental Pharmacology|June 23, 2011
Therapeutic potential of phosphodiesterase inhibitors in parasitic diseasesYasmin Shakur, Harry P de Koning, Hengming Ke, et al.
Cellular Signalling|May 8, 2007
Role of phosphodiesterase type 3A and 3B in regulating platelet and cardiac function using subtype-selective knockout miceBing Sun, Haiquan Li, Yasmin Shakur, et al.
Cardiovascular Drugs and Therapy|March 26, 2003
Comparison of the effects of cilostazol and milrinone on cAMP-PDE activity, intracellular cAMP and calcium in the heartYasmin Shakur, Miranda Fong, James Hensley, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Handbook of Experimental Pharmacology|June 23, 2011
Phosphodiesterases as targets for intermittent claudicationYongge Liu, Yasmin Shakur, Junichi Kambayashi
BMC Microbiology|March 9, 2006
Cyclic nucleotide specific phosphodiesterases of Leishmania majorAndrea Johner, Stefan Kunz, Markus Linder, et al.
Current Pharmaceutical Design|October 8, 2003
Cilostazol as a unique antithrombotic agentJunichi Kambayashi, Yongge Liu, Bing Sun, et al.
Handbook of Experimental Pharmacology|June 23, 2011
Therapeutic potential of phosphodiesterase inhibitors in parasitic diseasesYasmin Shakur, Harry P de Koning, Hengming Ke, et al.
Cellular Signalling|May 8, 2007
Role of phosphodiesterase type 3A and 3B in regulating platelet and cardiac function using subtype-selective knockout miceBing Sun, Haiquan Li, Yasmin Shakur, et al.
Cardiovascular Drugs and Therapy|March 26, 2003
Comparison of the effects of cilostazol and milrinone on cAMP-PDE activity, intracellular cAMP and calcium in the heartYasmin Shakur, Miranda Fong, James Hensley, et al.
Pageof 1